oroxine 125 mikrog tabletti
aspen pharma trading limited - levothyroxinum natricum pentahydricum - tabletti - 125 mikrog - levotyroksiininatrium
oroxine 150 mikrog tabletti
aspen pharma trading limited - levothyroxinum natricum pentahydricum - tabletti - 150 mikrog - levotyroksiininatrium
oroxine 175 mikrog tabletti
aspen pharma trading limited - levothyroxinum natricum pentahydricum - tabletti - 175 mikrog - levotyroksiininatrium
oroxine 200 mikrog tabletti
aspen pharma trading limited - levothyroxinum natricum pentahydricum - tabletti - 200 mikrog - levotyroksiininatrium
docetaxel orion 20 mg/ml infuusiokonsentraatti, liuosta varten
orion corporation - docetaxelum - infuusiokonsentraatti, liuosta varten - 20 mg/ml - dosetakseli
docetaxel orion 80 mg / 4 ml infuusiokonsentraatti, liuosta varten
orion corporation - docetaxelum - infuusiokonsentraatti, liuosta varten - 80 mg / 4 ml - dosetakseli
docetaxel orion 160 mg / 8 ml infuusiokonsentraatti, liuosta varten
orion corporation - docetaxelum - infuusiokonsentraatti, liuosta varten - 160 mg / 8 ml - dosetakseli
doxorubicin stada 2 mg/ml injektioneste, liuos
stada arzneimittel ag - doxorubicini hydrochloridum - injektioneste, liuos - 2 mg/ml - doksorubisiini
metronidazole vioser 5 mg/ml infuusioneste, liuos
vioser sa parenteral solution industry - metronidazole - infuusioneste, liuos - 5 mg/ml - metronidatsoli
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - mahalaukun kasvaimet - antineoplastiset aineet - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.